Selective Insolubility of α-Synuclein in Human Lewy Body Diseases Is Recapitulated in a Transgenic Mouse Model-Reference-Cited by-同舟云学术

Selective Insolubility of α-Synuclein in Human Lewy Body Diseases Is Recapitulated in a Transgenic Mouse Model

Published:2001-12 Issue:6 Volume:159 Page:2215-2225
ISSN:0002-9440
Container-title:The American Journal of Pathology
language:en
Short-container-title:The American Journal of Pathology

Author:

Kahle Philipp J.,Neumann Manuela,Ozmen Laurence,Müller Veronika,Odoy Sabine,Okamoto Noriko,Jacobsen Helmut,Iwatsubo Takeshi,Trojanowski John Q.,Takahashi Hitoshi,Wakabayashi Koichi,Bogdanovic Nenad,Riederer Peter,Kretzschmar Hans A.,Haass Christian

Publisher

Elsevier BV

Subject

Pathology and Forensic Medicine

Reference54 articles.

1. Molecular cloning of cDNA encoding an unrecognized component of amyloid in Alzheimer disease;Uéda;Proc Natl Acad Sci USA,1993

2. α-Synuclein in Lewy bodies;Spillantini;Nature,1997

3. NACP, a presynaptic protein, immunoreactivity in Lewy bodies in Parkinson's disease;Wakabayashi;Neurosci Lett,1997

4. Abnormal accumulation of NACP/α-synuclein in neurodegenerative disorders;Takeda;Am J Pathol,1998

5. Nigral and cortical Lewy bodies and dystrophic nigral neurites in Parkinson's disease and cortical Lewy body disease contain α-synuclein immunoreactivity;Irizarry;J Neuropathol Exp Neurol,1998

Cited by 218 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. ⍺-Synuclein levels in Parkinson's disease – Cell types and forms that contribute to pathogenesis;Experimental Neurology;2024-09

2. The involvement of α-synucleinopathy in the disruption of microglial homeostasis contributes to the pathogenesis of Parkinson’s disease;Cell Communication and Signaling;2024-01-12

3. Photo‐oxygenation of histidine residue inhibits α‐synuclein aggregation;The FASEB Journal;2023-11-14

4. Fiber deprivation and microbiome-borne curli shift gut bacterial populations and accelerate disease in a mouse model of Parkinson’s disease;Cell Reports;2023-09

5. In vivo effects of the alpha-synuclein misfolding inhibitor minzasolmin supports clinical development in Parkinson’s disease;npj Parkinson's Disease;2023-07-17